欢迎来到西安迈博睿(Mabioway)生物科技有限公司 Call: 15339069646 | E-mail: info@mabioway.cn 在线留言 |

服务热线

15339069646
网站导航
当前位置: 首页 > 产品展示 > 抗体产品 > 一抗 > 其他抗体
其他抗体
Anti-CD44v6 mAbs [BIWA-4 (Bivatuzumab)](MABL-3917)
  • Anti-CD44v6 mAbs [BIWA-4 (Bivatuzumab)](MABL-3917)

Anti-CD44v6 mAbs [BIWA-4 (Bivatuzumab)](MABL-3917)

简要描述:

For Research Use Only. Not for diagnostic or therapeutic use.

产品参数:

Cat. No.:MABL-3917

Application:in vivo, SPR, therapeutic, ELISA

Isotype:Engineer antibody

Species Reactivity:Human

Clone No.:BIWA‑4 (Bivatuzumab)

产品价格:¥0

详细介绍
Cat. No.
MABL-3917
Application
in vivo, SPR, therapeutic, ELISA
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
BIWA‑4 (Bivatuzumab)
From
Recombinant Antibody
Specificity
The antibody is specific for CD44v6. The antibody recognizes an epitope encoded by variant exon v6 of CD44. CD44v6 is a tumor‑associated antigen abundantly expressed in head and neck squamous cell carcinomas (HNSCC) and in normal squamous epithelium.
Alternative Names
CD44 antigen; CDw44; Epican; Extracellular matrix receptor III; ECMR‑III; GP90 lymphocyte homing/adhesion receptor; HUTCH‑I; Heparan sulfate proteoglycan; Hermes antigen; Hyaluronate receptor; Phagocytic glycoprotein 1; PGP‑1; Phagocytic glycoprotein I; PGP‑I; BIWA 4
UniProt
P16070
Immunogen
The antibody is the humanized version of the murine BIWA‑1.
Application Notes
The binding affinity of the antibody to CD44v6 was measured by surface plasmon resonance. The antibody demonstrated specific tumor localization when co‑administered with another antiCD44v6 antibody in mice (Verel et al., 2002; PMID: 11992408). The specificity of the humanized version was confirmed by ELISA (Kd=3.4 nM). In vivo experiments in mice showed good therapeutic efficacy, favorable biodistribution, and strong tumor uptake, with ¹⁸⁶Re‑labeled BIWA 4 treatment resulting in decreased tumor volume (US6972324B2). The radiolabeled humanized antibody was also evaluated in a clinical trial in patients with advanced squamous cell carcinoma of the head and neck, demonstrating promising antitumor activity (Börjesson et al., 2003; PMID: 14506195). This antibody was successfully used for immunohistochemistry on formalin‑fixed, paraffin‑embedded tissue sections to detect CD44v6 expression in squamous cell carcinomas of the head and neck, lung, esophagus, cervix, and vulva, as well as in selected normal tissues such as skin, tonsil, and squamous epithelium of the cervix and cornea. In flow cytometry, it specifically stained CD44v6‑positive tumor cell lines, including A431 and FaDu. The antibody efficiently internalized upon binding to CD44v6‑positive cells and exhibited selective tumor uptake in xenograft and clinical localization studies (Tijink et al., Clin. Cancer Res., 2006).
Antibody First Published
/
Note on publication
/
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.

 


服务咨询

留言框

  • 标题:

  • 留言内容:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 详细地址:

推荐产品

联系我们

Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有

地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层

电话:15339069646 邮箱:info@mabioway.cn

陕ICP备2021006339号